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Abstract
Background: The FCER2	gene,	via	encoding	of	the	CD23	receptor,	plays	an	important	
role	in	the	regulation	of	IgE	responses.	A	genetic	variant	of	the	FCER2	gene	(T2206C)	
was	previously	shown	to	be	associated	with	IgE	levels	in	asthmatic	children.	IgE	sen‐
sitization	has	also	been	 linked	to	 increased	 levels	of	fractional	exhaled	nitric	oxide	
(FENO).
Objective: To	investigate	whether	the	FCER2	T2206C	variant	influences	FENO	levels	
in	asthmatic	children	with	a	reported	use	of	inhaled	corticosteroids	(ICS).
Methods: This	cross‐sectional	study	involved	593	asthmatic	children	with	a	reported	
use	of	 ICS,	availability	of	FENO	measurements	and	genotyping	data	on	the	FCER2 
T2206C	variant	(rs28364072).	An	additive	genetic	model	was	assumed,	and	the	asso‐
ciation	between	the	FCER2	T2206C	variant	and	the	log‐transformed	(ln)	FENO	levels	
was	evaluated	using	linear	regression	analysis,	adjusted	for	age,	sex,	adapted	British	
Thoracic	Society	(BTS)	treatment	steps	and	atopy.
Results: The	mean	age	of	the	population	was	9.1	±	2.2	years,	and	the	median	of	FENO	
levels	was	13.0	ppb	with	an	interquartile	range	(IQR)	of	(8.0‐27.5	ppb).	The	minor	al‐
lele	(G)	frequency	of	rs28364072	was	29.6%,	and	each	extra	copy	of	the	G	allele	was	
significantly	associated	with	a	lower	level	of	the	geometric	mean	of	FENO	(log	scale,	
β	=	−0.12,	95%	CI:	−0.23,	−0.02).
Conclusion and Clinical Relevance: Our	results	showed	that	the	FCER2	T2206C	vari‐
ant	was	significantly	associated	with	 lower	FENO	levels	 in	carriers	of	 the	G	allele.	
Nevertheless,	this	SNP	contributed	little	to	the	variability	in	FENO	levels	in	this	pa‐
tient	population.	Our	findings	contribute	to	the	present	knowledge	on	FENO	in	asth‐
matic	children;	however,	future	replication	studies	are	required	to	establish	the	role	
of	this	gene	in	relation	to	FENO.
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1  | INTRODUC TION
Asthma	in	children	is	often	atopic,	IgE‐mediated1‐3	and	characterized	
by	chronic	airway	inflammation.4	The	key	regulator	of	IgE	in	asthma	
is	the	low‐affinity	IgE	receptor,	also	known	as	CD23.	CD23,	a	C‐type	
lectin,	 is	expressed	on	B	cells,	macrophages,	eosinophils,	 follicular	
dendritic	cells	and	platelets.5	Activation	of	this	receptor	suppresses	
the	production	of	IgE6	that	results	in	downregulation	of	the	IgE‐me‐
diated	immune	response.7	The	CD23	receptor	is	encoded	by	the	Fc	
fragment	 of	 the	 IgE	 receptor	 II	 (FCER2)	 gene	which	 is	 an	 11‐exon	
gene	 located	 at	 chromosome	 19p13.2.	 Variants	 of	 FCER2 could 
modify	 the	 IgE	synthesis.7	Furthermore,	 in	asthmatic	patients,	 the	
rs28364072	polymorphism	(T2206C)	in	FCER2	has	previously	been	
shown	 to	be	associated	with	elevated	 IgE,8,9	exacerbations,8‐10 in‐
creased	daily	need	of	inhaled	corticosteroids	(ICS),8,9	and	poor	lung	
function.9,10
Nitric	oxide	(NO)	is	a	biomarker	used	in	respiratory	disease	and	
results	 from	oxidation	of	 l‐arginine	 in	 the	presence	of	nitric	oxide	
synthase	(NOS).	Three	different	isoforms	of	NOS	exist:	two	consti‐
tutive	NOS	(cNOS)	isoforms	and	one	inducible	NOS	(iNOS)	isoform.	
The	expression	of	 iNOS	 is	boosted	by	 inflammatory	 stimulation.11 
NO,	at	higher	concentrations,	appears	to	function	as	an	inflammatory	
agent.12	Previous	studies	showed	that	the	fractional	exhaled	nitric	
oxide	(FENO)	was	raised	in	the	airways	of	patients	with	asthma11,13 
and	was	positively	associated	with	higher	IgE	levels	in	asthmatic	pa‐
tients.14,15	Many	factors	such	as	age,	height,	race,	use	and	adherence	
to	 asthma	 medication,	 diet,	 exercise,	 and	 environmental	 factors	
might	affect	FENO	levels.16,17	Dugas	et	al	suggested	that	CD23	has	a	
major	regulatory	effect	on	iNOS	activation	in	human	monocytes	and	
leads	to	NO	production.18	Furthermore,	Kolb	et	al19	found	that	the	
NOS	pathway	is	involved	in	IgE‐mediated	activation	of	monocytes.	
They	also	proposed	that	the	increase	of	CD23‐driven	cAMP	(cyclic	
adenosine	monophosphate)	in	monocytes	is	partly	linked	to	the	NOS	
pathway.19
A	study	in	Vietnamese	children	with	uncontrolled	and	untreated	
asthma	(n	=	32)20	showed	that	the	 levels	of	FENO	were	highest	 in	
the	homozygous	carriers	(CC)	of	rs28364072	variation	in	the	FCER2 
gene.	Their	results	imply	that	polymorphisms	in	the	FCER2	gene	are	
associated	with	FENO	 levels.	However,	no	 studies	have	evaluated	
this	 association	 in	 asthmatic	 children	 being	 treated	 with	 asthma	
medication.
In	 this	study,	we	aimed	to	 investigate	 the	association	between	
the	FCER2	T2206C	variant	and	FENO	levels	in	a	large	cohort	of	asth‐
matic	children	treated	with	inhaled	corticosteroids	(ICS).
2  | METHODS
2.1 | Study setting and population
The	 study	 was	 undertaken	 in	 the	 PACMAN	 (Pharmacogenetics	
of	 Asthma	medication	 in	 Children:	Medication	 with	 Anti‐inflam‐
matory	effects)	 cohort	 study.	Details	of	 the	 study	protocol	have	
been	described	elsewhere.21	In	short,	the	PACMAN	study	includes	
children	 (aged	 4‐12	 years)	 who	 were	 selected	 through	 pharma‐
cies	 that	 belonged	 to	 the	 Utrecht	 Pharmacy	 Practice	 Network	
for	 Education	 and	 Research	 (UPPER).22	 Children	 who	 regularly	
used	asthma	medication	 (Anatomical	Therapeutic	Chemical	 code	
R03),	 namely	 ≥3	 prescriptions	 within	 the	 last	 2	 years	 and	 ≥1	
prescription(s)	 in	the	last	6	months,	were	recruited	through	com‐
munity	 pharmacies	 in	 the	 Netherlands.21	 Selected	 children	 and	
their	parents	visited	their	own	pharmacy,	and	during	the	visits,	par‐
ents	filled	in	a	questionnaire	that	provided	information	about	their	
children:	respiratory	symptoms,	allergy,	asthma	diagnosis,	medica‐
tion	use	and	adherence,	socio‐demographic	factors,	and	environ‐
mental	factors.21	The	Asthma	Control	Questionnaire	(ACQ)23	was	
also	 included	in	the	questionnaire.	 In	addition,	FENO	levels	were	
measured	 (NIOX	Mino;	 Aerocrine),	 and	 saliva	 samples	were	 col‐
lected	for	DNA	extraction	(Oragene	DNA	Self‐Collection	kit;	DNA	
Genotek,	 Inc.,	Kanata,	ON,	Canada).	 In	 the	PACMAN	study,	daily	
ICS	dosages	(defined	daily	dosages	of	budesonide	equivalent)	were	
based	on	the	last	recorded	refill	prescription	in	the	pharmacy	prior	
to	 the	 study	 visit.	 The	 parents	 provided	 written	 informed	 con‐
sent,	and	the	PACMAN	cohort	study	was	approved	by	the	Medical	
Ethics	Committee	of	 the	University	Medical	Centre	Utrecht.	The	
study	 population	 for	 our	 analysis	 consisted	 of	 all	 asthmatic	 chil‐
dren	 treated	with	 inhaled	corticosteroids	 (ICS)	and	who	also	had	
FENO	measurements,	genotyping	and	questionnaire	data.
2.2 | Definition of fraction of nitric oxide in 
exhaled breath
FENO	was	measured	during	 the	baseline	visit	 at	 the	pharmacy	by	
using	a	single‐breath	on‐line	(SBOL)	technique	which	was	performed	
with	a	hand‐held	electrochemical	analyser	 (NIOX	Mino;	Aerocrine,	
Solna,	Sweden)	during	an	exhalation	time	of	6	seconds.24
2.3 | Genotyping
Genotyping	was	performed	using	Human	Core‐24	BeadChip	Marker	
information,	and	the	quality	control	(QC)	procedures	were	applied	to	
the	genotype	data.	Data	were	imputed	using	the	second	release	of	
the	Haplotype	Reference	Consortium25	(HRC)	(realises	1.1	2016)	by	
mean	Michigan	Imputation	Server.26	We	extracted	genotype	dosage	
for	 rs28364072	 in	 the	FCER2	 gene	with	a	high	 imputation	quality	
(Rsq	score	=	0.98).	The	Rsq	score	is	defined	as	the	ratio	of	the	sample	
variance	of	the	allele	dosage	during	imputation	to	the	expected	vari‐
ance	under	Hardy‐Weinberg	equilibrium	(HWE).27
2.4 | Potential confounders/covariables
Potential	 confounders/covariates	 consisted	 of	 age,	 sex,	 (adapted)	
British	 Thoracic	 Society	 guidelines28	 treatment	 steps	 (BTS)	 and	
atopy.	We	defined	treatment	step	as	follows:	step	0,	no	use	of	inhaled	
short‐acting	 β2‐agonist;	 step	 1,	 short‐acting	 β2‐agonist	 as	 needed;	
step	2,	step	1	plus	regular	ICS;	step	3,	step	2	plus	long‐acting	β2‐ago‐
nist;	step	4,	step	3	plus	oral	 leukotriene	receptor	antagonist.	Since	
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all	patients	were	required	to	be	on	ICS,	the	study	population	was	on	
BTS	treatment	step	2	or	above.
Atopy	was	specified	as	a	reported	history	of	allergic	rhinitis,	ec‐
zema,	or	food	allergy.	Asthma	control	was	measured	with	the	help	
of	 the	6‐item	version	of	 the	Asthma	Control	Questionnaire	 (ACQ)	
(investigates	 respiratory	 symptoms	 and	 need	 of	 short‐acting	 β2‐
agonists).29	 A	mean	 score	 of	 ACQ	≥	 0.75	 indicated	 ‘not	well‐con‐
trolled	asthma’	and	an	ACQ	score	of	<0.75	indicated	‘well‐controlled	
asthma’.23,30
2.5 | Functional annotation of SNPs in strong LD 
with rs28364072
We	 retrieved	 all	 proxy	 SNPs	 in	 high	 linkage	 disequilibrium	 (LD)	
(R2	 >	 0.8,	 limit	 distance	 100	 kb,	 and	 population	 panel	 CEU	 using	
1000	 Genomes	 project)	 with	 rs28364072	 in	 FCER2	 and	 checked	
their	predicted	functions,	effects	on	protein	structure,	gene	regula‐
tion,	and	splicing,	using	 the	HaploReg	v4.1	 (http://www.broad	insti	
tute.org/mamma	ls/haplo	reg/haplo	reg.php;	in	the	public	domain).
2.6 | Expression quantitative trait loci analysis
The	correlation	of	 the	SNP	 rs28364072	and	 its	proxies	 in	high	LD	
with	the	expression	level	of	FCER2	gene	in	whole	blood	was	checked	
(expression	quantitative	trait	loci	[eQTL]	analysis)	using	publicly	avail‐
able	 data	 from	 (GTEx)	 portal	 (GTEx	 portal:www.gtexp	ortal.org/
home/)	 and	 GeneNetwork.31	 Moreover,	 we	 checked	 the	 effect	 of	
the	SNP	on	FCER2	expression	across	different	tissues	using	the	GTEx	
portal.
2.7 | Statistical analyses
Descriptive	statistics	were	used	to	calculate	means	and	standard	
deviations	for	continuous	variables	and	percentages	for	categori‐
cal	variables.	For	continuous	variables	that	were	not	normally	dis‐
tributed,	the	median	and	interquartile	range	(IQR)	were	calculated.	
The	chi‐square	test	and	Mann‐Whitney	U	test	were	used	to	deter‐
mine	whether	there	was	a	significant	difference	in	characteristics	
between	children	with	well‐controlled	asthma	and	not	well‐con‐
trolled	asthma.	FENO	values	equal	to	zero	parts	per	billion	(ppb)	
were	set	at	2.5	ppb	(the	detection	limit	of	the	NIOX	Mino	=	5	ppb).	
Kruskal‐Wallis	 test	was	used	 to	assess	whether	 there	was	a	sta‐
tistically	significant	difference	 in	the	concentration	of	FENO	be‐
tween	 three	 genotype	 categories	 of	 FCER2	 rs28364072	 namely	
homozygous	 (GG),	 heterozygote	 (GA)	 and	 homozygous	 (AA).	 In	
pairwise	comparison,	Dunn's	pairwise	tests	(also	known	as	Dunn's	
post	hoc	tests)	were	used	on	each	pair	of	rs28364072	genotypes	
(GG	vs	AG,	GG	vs	AA,	and	AG	vs	AA)	to	investigate	the	differences	
in	FENO	levels	by	genotype	pairs.	To	control	for	multiple	testing,	
we	divided	0.05	by	the	number	of	 tests	 (n	=	3)	being	performed	
(Bonferroni	correction);	therefore,	we	considered	a	Dunn's	P‐value	
<0.016	(0.05/3)	statistically	significant.	Mann‐Whitney	U	test	was	
used	 to	 evaluate	 whether	 there	 was	 a	 significant	 difference	 in	
FENO	 levels	 between	 the	 two	 categories:	 carrier	 of	 the	mutant	
allele	(GG	and	AG	genotypes)	and	non‐carrier	of	the	G	allele	(AA	
genotype).	To	assess	whether	there	was	any	effect	of	ICS	dose	on	
the	levels	of	FENO	in	our	study	population,	we	tested	the	correla‐
tion	between	FENO	 levels	and	 ICS	dosage	using	 the	Spearman's	
rank	test.	We	also	tested	this	correlation	in	subgroups	of	carriers	
and	non‐carriers	of	the	FCER2	T2206C	variant.	Based	on	the	GINA	
guideline4	we	categorized	daily	ICS	dosage	into	three	categories:	
low,	medium	and	high	(Table	S1).	Kruskal‐Wallis	test	was	used	to	
assess	whether	 there	was	 a	 statistically	 significant	 difference	 in	
the	median	 FENO	 level	 between	 patients	 treated	with	 low,	me‐
dium	and	high	ICS	dosages.
An	 additive	 genetic	 model	 was	 assumed,	 and	 the	 association	
between	 the	 FCER2	 T2206C	 variant	 and	 FENO	 concentrations	
was	 assessed	 using	 linear	 regression.	As	 FENO	was	 not	 normally	
distributed,	 FENO	 levels	 were	 used	 as	 log‐transformed,	 natural	
logarithm	 (ln),	 for	 the	 regression	 analysis.	 The	 regression	 analysis	
was	adjusted	for	age	and	sex	in	Model	1,	and	Model	2	was	further	
adjusted	for	atopy	as	a	dichotomous	variable	with	two	categories	
(0	=	no	and	1	=	yes)	and	adapted	BTS	treatment	steps.	To	investi‐
gate	whether	the	association	would	differ	between	well‐controlled	
asthma	(ACQ	<	0.75)	and	not	well‐controlled	asthma	(ACQ	≥	0.75),	
we	estimated	the	regression	models	 in	both.	Next,	we	performed	
a	sensitivity	analysis	and	the	FENO	values	equal	to	0	ppb	were	set	
at	0	ppb	and	5	ppb,	respectively	and	the	analyses	were	repeated.	
The	HardyWeinberg	package32	(version	1.6.2)	for	R	was	applied	to	
assess	HWE	using	exact	 test	with	DOST	 (Double	One‐Sided	Tail)	
P‐value.33
Statistical	 significance	was	 considered	 at	 the	P‐value	 of	 <0.05	
(two‐sided).	SPSS	24.0	software	(IBM	Corporation)	was	used	for	the	
analysis.
3  | RESULTS
A	data	set	of	593	children	with	reported	use	of	ICS,	FENO	meas‐
urements	 and	 FCER2	 genotype	 information	 was	 available	 within	
the	 PACMAN	 cohort.	 The	 general	 characteristics	 of	 the	 study	
population	are	shown	in	Table	1.	The	mean	age	of	the	population	
was	9.1	±	2.2	years,	and	the	majority	of	children	were	boys	(62.1%).	
Of	 these	children;	82%	reported	a	history	of	atopy	and	59%	had	
well‐controlled	asthma.	The	median	value	of	FENO	was	13.0	ppb	
with	 an	 interquartile	 range	 (IOR)	 of	 8.0‐27.5	 ppb.	 The	 median	
value	 of	 FENO	was	 significantly	 lower	 in	well‐controlled	 asthma	
13.0	 ppb	 (IQR	 =	 8.0‐25.0	 ppb)	 compared	 to	 not	 well‐controlled	
asthma	16.0	ppb	(IQR	=	9.0‐31.8	ppb)	with	P	=	0.044.	FENO	values	
equal	to	zero	ppb	were	found	in	27	subjects	(19	boys)	with	a	mean	
age	of	7.9	±	2.1.	The	minor	allele	(G)	frequency	of	rs28364072	was	
29.6%,	and	10.5%	of	the	participants	were	homozygous	(GG)	carri‐
ers	of	the	FCER2	T2206C	variant.	The	SNP	was	in	HWE	in	the	total	
population	 (P	 =	0.051),	 in	 the	category	of	well‐controlled	asthma	
(P	 =	 0.121)	 and	 in	 the	 category	 of	 not	 well‐controlled	 asthma	
(P	=	0.219).
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3.1 | Levels of FENO in different FCER2 
variant genotypes
The	levels	of	FENO	were	compared	among	the	three	genotypes	of	
rs28364072	(Table	2	and	Figure	1).	The	FENO	levels	were	lowest	in	
children	with	GG	genotype	(10.0	ppb,	IQR:	7.0‐22.2	ppb)	and	highest	
in	AA	genotype	(16.0	ppb,	IQR:	9.0‐28.5	ppb).	In	pairwise	compari‐
son,	there	was	significant	evidence	(unadjusted	P‐value)	that	the	con‐
centration	of	FENO	was	statistically	significantly	different	between	
GG‐AA	genotypes	and	AG‐AA	genotypes	(Table	2).	After	adjustment	
for	multiple	 testing,	 the	FENO	 levels	 remained	significantly	differ‐
ent	between	genotypes	AA	and	AG	 (Table	2	and	Figure	1).	 In	 the	
category	of	well‐controlled	asthma	(n	=	341),	the	FENO	levels	were	
significantly	different	between	GG‐AA	genotypes	and	AG‐AA	gen‐
otypes;	however,	both	were	no	 longer	 significant	after	Bonferroni	
correction	 (Table	2).	 In	the	category	of	not	well‐controlled	asthma	
(n	=	240),	 there	were	no	 significant	 differences	 in	 FENO	 levels	 at	
all	 (P‐value	from	Kruskal‐Wallis	test	was	equal	0.339;	Table	2).	We	
also	found	a	significant	difference	in	the	FENO	concentrations	be‐
tween	the	carriers	of	the	mutant	allele	(GG	and	AG	genotypes)	and	
the	non‐carriers	of	the	G	allele	(AA	genotype)	in	the	total	population	
and	well‐controlled	asthma	category	(Table	3).
3.2 | Association of FCER2 variant with FENO levels
The	 associations	 of	 the	 FCER2	 variant	 with	 FENO	 levels	 are	 pre‐
sented	in	Table	4.	In	the	crude	model,	each	extra	copy	of	the	G	allele	
of	rs28364072	was	significantly	associated	with	a	lower	level	of	the	
geometric	mean	of	FENO	(log	scale,	β	=	−0.15,	95%	CI:	−0.26,	−0.05).	
When	we	adjusted	for	age	and	sex	(Model	1)	and	also	after	further	
adjustment	for	BTS	treatment	steps	and	a	reported	history	of	atopy	
(Model	2),	the	estimated	effects	remained	statistically	significant.
TA B L E  1  Characteristics	of	study	population
Baseline characteristics Total population
Well‐controlled
(ACQ < 0.75)
Not well‐controlled
(ACQ ≥ 0.75) Pa
n 593 341/581b 240/581b  
Age,	mean	(±	SD) 9.1	±	2.2 9.0	±	2.1 9.2	±	2.2  
Male,	%	(n) 62.1	(368) 62.8	(127) 61.7	(148) 0.795
History	of	atopyc	%	(n) 82	(484/590) 82.4	(280/340) 82.5	(198/240) 0.963
Eczemac,	%	(n) 66.9	(394/589) 65.9	(224/340) 69.9	(167/239) 0.313
Food	allergyc,	%	(n) 52.1	(306/587) 48.4 (164/339) 58.0 (138/238) 0.023
Hayfeverc,	%	(n) 46.4	(269/580) 45.4	(152/335) 48.5	(114/235) 0.460
Family history of atopy
Paternal	asthmac	%	(n) 29.9	(163/546) 27.8	(88/317) 32.9	(72/219) 0.203
Paternal	eczemac	%	(n) 27.6	(147/533) 28.0	(87/311) 27.7	(59/213) 0.945
Paternal	hayfeverc	%	(n) 38.2	(206/539 38.1	(119/312) 39.2	(85/217) 0.811
Maternal	asthmac	%	(n) 26.6	(147/553) 21.1 (66/313) 33.2 (76/229) 0.002
Maternal	eczemac	%	(n) 39.9	(222/556) 36.5	(116/318) 44.1	(100/227) 0.075
Maternal	hayfeverc	%	(n) 44.3	(247/557) 43.2	(137/317) 46.3	(106/229) 0.476
Adapted BTS treatment stepd % (n)
2 69.1	(410) 74.7 (248) 66.8 (155) 0.012
3 20.9	(124) 20.8 (69) 22.4 (52)
4 6.9	(41) 4.5 (15) 10.8 (25)
Minor	allele	frequency	FCER2	variant	% 29.6 29.5 29.9 0.982
Genotype distribution T2206C variant
Homozygous	wild‐type	(AA)	%	(n) 51.4	(305) 51.6	(176) 50.8	(122)
Heterozygous	(AG)	%	(n) 38.1	(226) 37.8	(129) 38.3	(92)
Homozygous	variant	(GG)	%	(n) 10.5	(62) 10.6	(36) 10.8	(26)
FENO	ppb,	median	(IQR) 13.0	(8.0‐27.5) 13.0 (8.0‐25.0) 16.0 (9.0‐31.8) 0.044
ACQ	b	score,	median	(IQR) 0.5	(0.17‐1.17) 0.17 (0.0‐0.5) 1.3 (1.0‐1.8) 0.000
ACQ,	Asthma	Control	Questionnaire;	FENO,	fractional	exhaled	nitric	oxide;	IQR,	Interquartile	range
aP‐value,	To	evaluate	the	significant	difference	between	the	two	categories,	well‐controlled	asthma	vs	not	well‐controlled	asthma,	using	chi‐square	
test	or	Mann‐Whitney	U	test.	
bIn	the	total	population,	data	on	the	Asthma	Control	Questionnaire	(ACQ)	were	missing	in	12	subjects.	
cData	were	not	available	for	the	total	population.	
d18	children	were	on	ICS	plus	leukotriene	receptor	antagonist	treatment.	
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3.3 | Association of FCER2 variant with FENO levels 
stratified by ACQ scores
We	 tested	 the	 association	 between	 the	 variant	 and	 FENO	 levels	
when	 the	 total	population	was	 stratified	 in	well‐controlled	asthma	
(ACQ	<	0.75)	and	not	well‐controlled	asthma	(ACQ	≥	0.75).	In	Model	
2,	adjusted	for	age,	sex,	BTS	treatment	steps	and	atopy,	each	extra	
copy	of	the	G	allele	of	rs28364072	was	significantly	associated	with	a	
lower	level	of	the	geometric	mean	of	FENO	(log	scale,	β	=	−0.17,	95%	
CI:	−0.30,	−0.04)	 among	children	with	well‐controlled	asthma.	We	
did	not	observe	any	significant	association	(log	scale,	β	=	−0.08,	95%	
CI:	−0.25,	0.09)	between	the	FCER2	variant	and	FENO	levels	in	the	
not	well‐controlled	asthma	group	(Table	4).	However,	the	point	esti‐
mate	was	in	the	same	direction	as	well‐controlled	asthma	category.
We	performed	sensitivity	analyses	whereby	the	FENO	values	equal	
to	0	ppb	were	set	at	0	and	5	ppb,	respectively.	The	results	of	these	
analyses	were	similar	to	the	results	of	our	original	analyses.	(Table	S2).
3.4 | Correlation of FENO levels and ICS 
daily dosage
Data	 on	 ICS	 dosage	 were	 available	 for	 475	 out	 of	 593	 subjects.	
There	 was	 no	 correlation	 between	 FENO	 levels	 and	 ICS	 dosage	
(Spearman's	 rank	correlation	coefficient	 [RS]	=	−0.016,	P	=	0.736).	
When	subjects	were	grouped	according	to	defined	daily	ICS	dosage	
(low,	medium,	 high),	 higher	FENO	 levels	 could	be	observed	 in	 the	
patients	 treated	with	 low	dosages	of	 ICS	category	 (median	FENO:	
17.0ppb	[IQR:	8.0‐30.0])	compared	to	patients	treated	with	medium	
ICS	 dosages	 (median	 FENO:	 14.00	 ppb	 [IQR:	 8.0‐23.0])	 and	 high	
ICS	dosages	(median	FENO:	11.5	ppb	[IQR:	7.0‐25.7]);	however,	the	
differences	were	not	statistically	significant.	In	addition,	there	was	
no	significant	correlation	between	FENO	 levels	and	 ICS	dosage	 in	
carriers	 or	 non‐carries	 of	 the	FCER2	 T2206C	variant	 (RS	=	0.025,	
P	=	0.703	and	RS	=	−0.038,	P	=	0.554,	respectively).
3.5 | Functional annotation and eQTL 
analysis of rs28364072
Functional	 annotation,	 using	 Haploreg	 v4.1	 data,	 shows	 that	
rs28364072	has	several	proxy	variants	(D′	=	1	and	R2	>	0.8),	but	they	
are	all	 intronic	 and	 synonymous,	without	 any	predicted	 functions,	
rs28364072 Genotypes FENOappb (IQR)
Pairwise comparison of 
FENO levels Pb
Total population (n = 593)
Homozygous	variant	(GG) 10.0	(7.0‐22.2) GG‐AG 0.541
Heterozygous	(AG) 12.0	(7.0‐27.2) GG‐AA 0.029
Homozygous	wild‐type	(AA) 16.0	(9.0‐28.5) AG‐AA 0.014
Well‐controlled (n = 341)a
Homozygous	variant	(GG) 10.0	(7.0‐20.8) GG‐AG 0.526
Heterozygous	(AG) 12.0	(7.0‐23.0) GG‐AA 0.041
Homozygous	wild‐type	(AA) 14.5	(8.0‐28.8) AG‐AA 0.029
Not well‐controlled (n = 240)a
Homozygous	variant	(GG) 14.0	(7.0‐35.8) GG‐AG 0.339c
Heterozygous	(AG) 13.0	(7.0‐36.0) GG‐AA
Homozygous	wild‐type	(AA) 18.0	(10.0‐28.5) AG‐AA
Abbreviation:	FENO,	fractional	exhaled	nitric	oxide.
aIn	the	total	population,	data	on	the	Asthma	Control	Questionnaire	(ACQ)	were	missing	in	12	
subjects.	
bTested	with	Dunn's	P‐value	for	pairwise	comparison	and	a	Bonferroni‐corrected	P‐value	lower	
than	0.016	(0.05/3)	was	considered	statistically	significant.	
*P‐value	from	Kruskal‐Wallis	test.	
TA B L E  2  Concentration	of	FENO	
among	genotypes	of	rs28364072
F I G U R E  1  Concentration	of	FENO	among	genotypes	of	
FCER2	T2206C	variant	(rs28364072).	FENO,	fractional	exhaled	
nitric	oxide.	The	Kruskal–Wallis	test	was	used	and	in	pairwise	
comparison,	a	Dunn's	P‐value	<	0.016	(0.05/3)	was	considered	
statistically	significant.
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(Table	 S3).	 Moreover,	 the	 cis‐eQTL	 data	 from	 GTEx	 portal	 and	
GeneNetwork31	 showed	 that	 the	minor	 allele	G	of	 rs28364072	 is	
significantly	 associated	 with	 reduced	 expression	 levels	 of	 FCER2 
in	whole	 blood	 (Table	 S4	 and	 Figure	 S1	 and	 Figure	 S2).	 Together,	
these	data	may	support	the	notion	that	rs28364072	has	an	effect	on	
FCER2	gene	expression	and	function.
4  | DISCUSSION
In	our	population‐based	study,	we	assessed	the	association	between	
the	FCER2	T2206C	variant	and	FENO	levels	in	children	with	asthma	
and	reported	use	of	ICS.	Our	results	showed	that	the	variation	in	the	
FCER2	gene	was	significantly	associated	with	lower	levels	of	FENO	in	
the	total	population	and	in	well‐controlled	asthmatic	patients.	There	
was	no	statistically	significant	association	between	the	FCER2	poly‐
morphism	and	levels	of	FENO	in	not	well‐controlled	asthma	group	
which	might	be	explained	by	the	small	sample	size	of	this	group.
To	 the	best	of	our	knowledge,	 the	current	study	 is	 the	 first	 to	
evaluate	 the	 association	 between	 the	 FCER2	 T2206C	 variant	 and	
FENO	 levels	 among	 asthmatic	 children	 using	 ICS.	 So	 far	 only	 one	
study	has	investigated	the	same	association	but	in	mild‐to‐moderate	
uncontrolled	and	untreated	asthmatic	patients	among	Vietnamese	
children	(n	=	32),	and	they	found	that	FENO	levels	were	significantly	
higher	in	subjects	with	the	FCER2	gene	mutation.20	However,	due	to	
a	small	sample	size	they	were	not	able	to	define	a	specific	FENO	level	
that	was	associated	with	the	FCER2	gene	variation.20	In	the	study	by	
Nguyen‐Thi‐Bich	et	al,20	all	subjects	with	uncontrolled	asthma	were	
not	 on	medication	 for	 at	 least	 one	month	 before	 inclusion,	 while	
in	the	PACMAN	study	all	subjects	were	on	 ICS	treatment	and	 ICS	
therapy	 is	 known	 to	decrease	FENO	 levels.34	 In	 addition,	 the	 fre‐
quency	of	the	rs28364072	homozygous	variant	of	the	FCER2	gene	
was	slightly	higher	among	Vietnamese	children	(15.6%)	than	(10.5%)	
in	 the	 mainly	 Caucasian	 children	 (91.4%)	 in	 the	 PACMAN	 study.	
Moreover,	the	sample	size	(n	=	593)	of	the	current	study	was	roughly	
19	times	larger	than	the	Vietnamese	study	(n	=	32).
It	has	previously	been	shown	that	IgE	is	associated	with	FENO	
levels	in	children	with	asthma	and	allergy.14,15	The	low‐affinity	IgE	
receptor,	 CD23,	 by	 nature	 inhibits	 IgE	 production.6 The FCER2 
gene	 affects	 the	 inflammatory	 mechanisms	 and	 results	 in	 the	
variability	 in	 the	 response	 to	 ICS	 in	asthma.35	The	T2206C	vari‐
ant	 is	 located	 in	 splicing	 region	 of	 intron	 9	 of	 FCER2	 and	might	
lead	 to	 alternative	 splicing	 and	 changes	 of	 the	 gene	 transcript	
length.	Tantisira	et	al	showed	that	the	T2206C	variant	was	asso‐
ciated	with	lower	FCER2	gene	expression.9	This	was	suggested	to	
be	 a	 possible	 mechanism	 for	 the	 higher	 IgE	 levels	 among	 carri‐
ers	of	the	mutant	(C)	allele	in	their	findings.9	In	animal	models,	it	
was	 confirmed	 that	 absence	 of	 CD23	 (CD23‐/‐)	 in	 the	 knockout	
mice	 resulted	 in	 elevated	 IgE‐mediated	 response	 compared	with	
TA B L E  3  Concentration	of	FENO	between	carries	and	non‐
carriers	of	the	G	allele	of	rs28364072
rs28364072 variation n
FENO ppb median 
(IQR) Pa
Total population (n = 593)
Carriers	of	the	variant	
(GG/AG)
288 12.0	(7.0‐25.7) 0.004
Non‐carriers	of	the	
variant	(AA)
305 16.0	(9.0‐28.5)
Well‐controlled category (n = 341)b
Carriers	of	the	variant	
(GG/AG)
165 11.0	(7.0‐23.0) 0.010
Non‐carriers	of	the	
variant	(AA)
176 14.5	(8.0‐28.8)
Not well‐controlled category (n = 240)b
Carriers	of	the	variant	
(GG/AG)
118 13.0	(7.0‐36.0) 0.146
Non‐carriers	of	the	
variant	(AA)
122 18.0	(10.0‐28.5)
Abbreviations:	FENO,	fractional	exhaled	nitric	oxide;	IQR,	Interquartile	
range.
aP‐value,	Tested	with	Mann‐Whitney	U	test.	
bIn	the	total	population,	data	on	the	Asthma	Control	Questionnaire	
(ACQ)	were	missing	in	12	subjects.	
TA B L E  4  Regression	coefficients	and	95%	confidence	intervals	describing	the	association	between	rs28364072	variation	of	the	FCER2 
gene	(per	copy	of	the	G	allele)	and	the	concentration	of	FENO
Crude Model 1 Model 2
FENOa Effect allele β (95% CI) P‐value  β (95% CI) P‐value β (95% CI) P‐value
Total	population	
(n	=	593)
G −0.15 (−0.26, −0.05) 0.005 −0.12 (−0.22, −0.02) 0.021 −0.12 (−0.23, −0.02) 0.018
Well‐controlleda 
(n	=	341)
G −0.18 (−0.32, −0.05) 0.007 −0.16 (−0.29, −0.03) 0.019 −0.17 (−0.30, −0.04) 0.011
Not	well‐con‐
trolleda	(n	=	240)
G −0.12	(−0.29,	0.06) 0.190 −0.09	(−0.25,	0.08) 0.306 −0.08	(−0.25,	0.09) 0.331
Note: In	the	total	population,	data	on	the	Asthma	Control	Questionnaire	(ACQ)	were	missing	in	12	subjects.	Crude,	only	SNP;	Model	1,	adjusted	for	
age	and	sex;	Model	2,	Model	1	further	adjusted	for	(adapted)	British	Thoracic	Society	(BTS)	treatment	steps	and	atopy.
Abbreviations:	ACQ,	Asthma	Control	Questionnaire;	CI,	Confidence	Interval;	FENO,	Fractional	exhaled	Nitric	Oxide;	Not	well‐controlled,	
ACQ	≥	0.75;	Well‐controlled,	ACQ	<	0.75.
aFENO	levels	were	used	as	log‐transformed	(ln).	
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wild‐type	CD23+/+.36,37	In	addition,	use	of	corticosteroids	might	be	
associated	with	a	decrease	in	CD23	expression,38	as	Tantisira	et	al9 
noticed	that	the	highest	IgE	levels	were	detected	in	individuals	who	
were	homozygote	(CC)	for	the	FCER2	T2206C	variant	and	on	ICS	
treatment.	However,	in	our	study	population	we	did	not	observe	a	
statistically	significant	effect	of	ICS	dosage	on	FENO	levels.	There	
is	some	evidence	from	the	literature	that	during	an	inflammatory	
response	the	CD23	receptor	induces	iNOS	activation	that	in	turn	
leads	 to	 NO	 production	 (Figure	 S3).18	 As	 shown	 previously,	 ge‐
netic	expression	of	CD23	decreased	in	individuals	homozygous	for	
T2206C	variant	compared	with	the	two	other	genotypes,9	which	is	
in	line	with	eQTL	data	demonstrating	decreased	expression	levels	
of	FCER2	 in	the	carriers	of	T2206C	variant	(Table	S3).	This	might	
lead	to	less	NO	production	and	consequently	lower	levels	of	FENO	
among	 carriers	 of	 the	 variant;	 hence,	 the	observed	 lower	FENO	
levels	in	carriers	of	the	FCER2	T2206C	variant	is	plausible.
It	 should	be	noted	 that	children	 in	our	study	with	not	well‐con‐
trolled	 asthma	 had	 a	 high	 percentage	 of	 food	 allergy	 and	maternal	
asthma	(Table	1).	It	has	been	shown	that	food	allergy	is	associated	with	
an	increased	risk	of	hospitalization	and	use	of	systematic	corticoste‐
roids	due	to	asthma.39,40	In	addition,	it	has	been	reported	that	maternal	
asthma	is	a	crucial	risk	factor	for	developing	asthma	in	childhood.41,42
In	our	study,	compared	to	non‐carriers	of	FCER2	T2206C	vari‐
ant,	 FENO	 levels	 in	 the	 carriers	 of	 the	 variant	 were	 significantly	
lower	with	a	median	difference	of	4ppb	(Table	3).	Further	research	
is	needed	to	monitor	FENO	over	time	in	FCER2	T2206C	carriers	to	
better	understand	the	clinical	relevance	of	this	finding.
A	major	strength	of	this	study	was	the	availability	of	information	
on	 asthma	 symptoms	 and	 FENO	 measurements	 in	 a	 large	 real‐life	
population	of	paediatric	patients.	Still,	some	limitations	need	to	be	ad‐
dressed.	First,	atopy	was	defined	based	on	parental	reporting	 in	the	
questionnaire	and	was	not	defined	based	on	a	skin	prick	test.	The	lack	
of	an	objective	criterion	 such	as	 the	 skin	prick	 test	 thus	might	 lead	
to	both	an	underestimation	(in	case	of	asymptomatic	patients)	and	an	
overestimation	of	atopy.	Similarly,	asthma	symptoms	were	parent‐re‐
ported	which	might	be	prone	to	over‐	or	underestimation.	Lastly,	as	
gene	expression	is	tissue	specific,	it	would	be	better	to	also	check	the	
association	between	T2206C	variant	 and	FCER2	 gene	expression	 in	
lung	tissue;	however,	so	far,	eQTL	data	from	lung	tissue	is	either	not	
available	or	only	in	very	small	sample	size.31
To	conclude,	we	observed	that	the	FCER2	T2206C	variant	was	
significantly	associated	with	 lower	 levels	of	FENO	in	children	with	
well‐controlled	asthma	treated	with	ICS.	However,	this	SNP	contrib‐
uted	little	to	the	variability	in	FENO	levels	in	this	patient	population.	
We	 acknowledge	 that	 the	 exact	 mechanism	 by	 which	 the	 FCER2 
T2206C	variant	could	modify	FENO	levels	needs	to	be	further	ex‐
plored	and	that	future	replication	studies	are	required	to	establish	
the	role	of	this	gene	in	relation	to	FENO.
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